A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma

Blood

Volumn 122, Issue 6, 2013, Pages 951-957

  Purdue, Mark P ^a   Hofmann, Jonathan N ^a   Kemp, Troy J ^b   Chaturvedi, Anil K ^a   Lan, Qing ^a   Park, Ju Hyun ^c   Pfeiffer, Ruth M ^a   Hildesheim, Allan ^a   Pinto, Ligia A ^b   Rothman, Nathaniel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c Seoul Natinonal University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BIOLOGICAL MARKER; CXCL13 CHEMOKINE; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN RECEPTOR 2; CXCL13 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOLOGY; MIDDLE AGED; RISK; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; CHEMOKINE CXCL13; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84886904255     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-481077     Document Type: Article

References (34)

1. Hartge P, Wang SS, Bracci PM, Devesa SS, Holly EA. Non-Hodgkin Lymphoma. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention, 3rd ed. New York: Oxford University Press; 2006:898-918.
2. Purdue MP, Lan Q, Martinez-Maza O, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood. 2009;114(13):2730-2732.
3. Purdue MP, Lan Q, Bagni R, Hocking WG, Baris D, Reding DJ, Rothman N. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res. 2011; 71(14):4898-4907.
4. De Roos AJ, Mirick DK, Edlefsen KL, et al. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res. 2012; 72(18):4733-4743.
5. Gu Y, Shore RE, Arslan AA, et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control. 2010;21(8):1323-1333.
6. Saberi Hosnijeh F, Krop EJ, Scoccianti C, et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1577-1584.
7. Vermeulen R, Hosnijeh FS, Portengen L, et al. Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1925-1927.
8. Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6 Suppl):251S-272S.
9. Hayes RB, Reding D, Kopp W, et al; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6 Suppl):349S-355S.
10. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110(2):695-708.
11. Chaturvedi AK, Kemp TJ, Pfeiffer RM, et al. Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1902-1911.
12. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998;187(4):655-660.
13. Widney DP, Gui D, Popoviciu LM, et al. Expression and function of the chemokine, cxcl13, and its receptor, cxcr5, in AIDS-associated non-Hodgkin’s lymphoma. AIDS Res Treat. 2010; 2010:164586.
14. Husson H, Freedman AS, Cardoso AA, et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol. 2002;119(2): 492-495.
15. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110(9):3316-3325.
16. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA. 1990;87(8): 3127-3131.
17. Aderka D, Engelmann H, Shemer-Avni Y, et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res. 1992;11(3):157-159.
18. Brockhaus M. Soluble TNF receptor: what is the significance? Intensive Care Med. 1997;23(8): 808-809.
19. Batten M, Fletcher C, Ng LG, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. 2004;172(2): 812-822.
20. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010;171(3):267-276.
21. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6):482-493.
22. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7): 2700-2707.
23. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol. 2001;33(4): 409-420.
24. Jacobi J, Tam BY, Wu G, Hoffman J, Cooke JP, Kuo CJ. Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia. Circulation. 2004; 110(16):2424-2429.
25. Wada H, Satoh N, Kitaoka S, et al. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis. 2010;208(2): 512-517.
26. Aref S, El Sherbiny M, Goda T, Fouda M, Al Askalany H, Abdalla D. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology. 2005;10(2):131-134.
27. Faderl S, Do KA, Johnson MM, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood. 2005; 106(13):4303-4307.
28. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 2006;16(5):405-411.
29. Mathy NL, Scheuer W, Lanzendörfer M, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. 2000;100(1): 63-69.
30. Tang W, Wang W, Zhang Y, Liu S, Liu Y, Zheng D. TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner. Cell Res. 2009;19(6):758-767.
31. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G. Amylin: history and overview. Diabet Med. 1997;14 Suppl 2:S9-S13.
32. Passam FH, Sfiridaki A, Pappa C, et al. Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol. 2008;30(1):17-25.
33. Rubio-Moscardo F, Blesa D, Mestre C, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood. 2005;106(9): 3214-3222.
34. Chao C, Page JH. Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168(5):471-480.